CGRP receptor antagonists clinical trials
A class of medicines: the studies that test any of its 6 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Calcitonin Gene-Related Peptide Receptor Antagonists.
Get an email when these change. Save the cgrp receptor antagonists studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Olcegepant
- 1
Studies by the year they started
147 studies that test it; most in 2022 (22); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 19 |
| 2020 | 15 |
| 2021 | 16 |
| 2022 | 22 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 11 |
| 2026 | 16 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 102 · Other 46
Pfizer (40) · Amgen (23) · AbbVie (17) · Allergan (13) · Mayo Clinic (9) · Novartis Pharmaceuticals (7) · Danish Headache Center (6) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 148
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyRecruitingPhase 4Mayo ClinicNCT06972056Written as Atogepant 60 mg
- A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare ProfessionalsNot yet recruitingNot applicableChinese PLA General HospitalNCT07918053Written as Rimegepant 75 mg ODT
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigraineRecruitingPhase 3PfizerNCT04743141Written as Rimegepant (PF-07899801)
- Randomized Study in Children and Adolescents With Migraine: Acute TreatmentRecruitingPhase 3PfizerNCT04649242Written as Rimegepant/BHV3000
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentRecruitingPhase 1University of South FloridaNCT07667621Written as Rimegepant
- A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaRecruitingPhase 4PfizerNCT07685769Written as Rimegepant 75 mg ODT
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsRecruitingPhase 3PfizerNCT05156398Written as Rimegepant
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineRecruitingPhase 3PfizerNCT07729462Written as Rimegepant
- A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineRecruitingPhase 4PfizerNCT07609914Written as Rimegepant
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingPhase 3AbbVieNCT06810505Written as Atogepant
- A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineNot yet recruitingNot applicableAmerican Center for Psychiatry and NeurologyNCT07861412Written as intranasal zavegepant
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingPhase 3AbbVieNCT05711394Written as Atogepant
- Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster HeadacheNot yet recruitingPhase 2The University of Texas Health Science Center, HoustonNCT07714369Written as Zavegepant 20 mg
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineRecruitingPhase 1PfizerNCT06995729Written as Zavegepant
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine HeadacheRecruitingPhase 4Antonios LikourezosNCT06473597Written as Rimegepant
- Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRecruitingPhase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07835035Written as Rimegepant
- Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineNot yet recruitingPhase 4Konrad Peter WeberNCT07826910Written as Atogepant 60 mg
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsRecruitingPhase 4Mayo ClinicNCT06401642Written as Zavegepant
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RecruitingPhase 3AbbVieNCT05125302Written as Ubrogepant
- Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07812467Written as Rimegepant
See all 148 studies that test one of the cgrp receptor antagonists →
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Results posted1
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineOct 28, 2026NCT03832998